Hepatic encephalopathy (maintenance treatment) - rifaximin: evaluation report 2
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
01 - Consultee comments on the ACD – British Liver Trust
02 - Consultee comments on the ACD – Foundation for Liver Research
03 - Consultee comments on the ACD – Norgine
04 - Consultee comments on the ACD – Royal College of Nursing
05 - Clinical expert comments on the ACD – Moreea
06 - Clinical expert comments on the ACD – Shawcross
07 - Public comments on the ACD received via the NICE website
08 - Additional evidence submitted by Norgine
09 - Review of additional evidence submitted by Peninsula Technology Assessment Group
10 – Statement submitted by Andrew Langford following sight of the committee papers
* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *
Hepatic encephalopathy (maintenance treatment) - rifaximin: evaluation report 2
27 November 2013 (3.38 Mb 48 sec) |
This page was last updated: 26 November 2013